Robuta

Sep 16, 2025 - Experts in the know say Sarepta’s Elevidys Duchenne therapy may overstate how much gene it delivers — raising new questions about its true benefit.

Oct 10, 2025 - After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without long-promised treatments.

Dec 26, 2024 - Marks' unilateral decision to overrule three different review teams and approve the Duchenne therapy looks even more surprising on a close examination.

Sarepta, though, may try to seek accelerated approval using Phase 2 data that's due imminently, along with results from another, smaller trial.

Nov 18, 2025 - Risk of “acute, serious, and life-threatening” heart inflammation is now on the label of Sarepta's gene therapy for Duchenne muscular dystrophy.

Nov 20, 2025 - Today's biotech news includes Pfizer's mRNA-based flu shot offered better protection than standard vaccine, Novartis in North Carolina, etc.

Jun 19, 2025 - With a tragedy in the news — the death of a second child tied to the therapy — the company faces market consequences, too.

Aug 5, 2025 - Sarepta Therapeutics is in the news because of its gene therapy for Duchenne muscular dystrophy. STATus Report host Alex Hogan goes behind the headlines.

Dec 17, 2025 - Ingram has taken on unnecessary risks for Duchenne patients, and hasn't served biotech investors well either.

Jun 18, 2025 - Gene therapy holds promise for treating Duchenne muscular dystrophy. But after a second Elevidys death, the system must work better.

Jul 24, 2025 - A muscular dystrophy disease is devastating on its own, but Sarepta Therapeutics' Elevydis, currently shelved, had offered hope.

Nov 26, 2025 - Today's biotech news covers Sarepta being cleared to test new safety regimen for Duchenne drug, the FDA approving Otsuka's kidney drug, etc.

Oct 10, 2025 - Sarepta says it has what could be the first gene therapy for limb girdle muscular dystrophy. But getting through the FDA may be tough.

An erroneous report of rhabdomyolysis in a patient enrolled in a Duchenne trial was the latest safety worry to send shares in a gene therapy biotech spiraling.

Nov 20, 2025 - In this week's edition of "Adam's Biotech Scorecard," Adam also lays out what he's grateful for in biotech this Thanksgiving season.

Jul 21, 2025 - We’ve come so far against Duchenne, two mothers say. Despite recent setbacks, we must keep going — and save room for risks.

An experimental Duchenne drug developed with a newer technology may be more potent than Sarepta's marketed treatment Exondys 51. But early data also...